Lupin zooms on launching Regional Reference Laboratory in Bengaluru

Lupin is currently trading at Rs. 678.80, up by 18.45 points or 2.79% from its previous closing of Rs. 660.35 on the BSE.

The scrip opened at Rs. 666.40 and has touched a high and low of Rs. 680.75 and Rs. 660.30 respectively. So far 51172 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 797.00 on 20-Apr-2022 and a 52 week low of Rs. 583.05 on 25-May-2022.

Last one week high and low of the scrip stood at Rs. 680.75 and Rs. 656.75 respectively. The current market cap of the company is Rs. 30884.13 crore.

The promoters holding in the company stood at 47.08%, while Institutions and Non-Institutions held 42.52% and 10.40% respectively.

Lupin has launched its new state-of-the-art Regional Reference Laboratory in Bengaluru, Karnataka, as part of the expansion of its diagnostics network. The new laboratory marks a significant step forward in Lupin Diagnostics' mission to provide accessible and affordable diagnostics and preventive healthcare services across India. The Regional Reference Laboratory complements the company's existing network of 25 laboratories and more than 410 collection centers across India.

The new laboratory in Bengaluru is equipped with cutting-edge technologies and staffed by highly qualified clinical experts, enabling Lupin Diagnostics to deliver high quality and reliable diagnostic services to patients and consumers across Bengaluru and neighboring cities.

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.